Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Net Margin (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Net Margin for 6 consecutive years, with 895.09% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 432581.0% to 895.09% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1256.81% through Dec 2025, up 323214.0% year-over-year, with the annual reading at 1256.81% for FY2025, 323214.0% up from the prior year.
  • Net Margin for Q4 2025 was 895.09% at TScan Therapeutics, up from 1422.14% in the prior quarter.
  • The five-year high for Net Margin was 271.99% in Q4 2023, with the low at 5906.9% in Q2 2024.
  • Average Net Margin over 5 years is 1516.18%, with a median of 630.81% recorded in 2021.
  • The sharpest move saw Net Margin plummeted -514308bps in 2024, then skyrocketed 470560bps in 2025.
  • Over 5 years, Net Margin stood at 497.55% in 2021, then dropped by -22bps to 604.94% in 2022, then surged by 55bps to 271.99% in 2023, then tumbled by -1820bps to 5220.9% in 2024, then soared by 83bps to 895.09% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 895.09%, 1422.14%, and 1201.3% for Q4 2025, Q3 2025, and Q2 2025 respectively.